Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03615105 · ClinicalTrials.gov registry record · Phase 2
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT03615105: Clinical Trial Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03615105 is a Phase 2 study that was terminated before completion, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03615105, a Phase 2 study, was terminated before completion, sponsored by Memorial Sloan Kettering Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study is being done to learn whether a new method to prevent rejection between the donor immune system and the patient's body is effective.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Busulfan
- DRUG Thiotepa
- RADIATION Hyperfractionated total body irradiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2018-07-25 |
| Est. Completion | 2024-03-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03615105
The ClinicalTrials.gov registry entry for NCT03615105 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT03615105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03615105 about?
NCT03615105 is a clinical study titled "Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors". This study is being done to learn whether a new method to prevent rejection between the donor immune system and the patient's body is effective.
What is the current status of trial NCT03615105?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2018-07-25. Estimated completion is 2024-03-06.
What interventions are being tested in trial NCT03615105?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Busulfan (DRUG), Thiotepa (DRUG), Hyperfractionated total body irradiation (RADIATION).
Who is sponsoring clinical trial NCT03615105?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.